Tokyo, Japan (June 14, 2021) – Daiichi Sankyo Company, Limited today announced that its affiliate, the Japan Research Foundation for Clinical Pharmacology* (headquarters, Tokyo; Director General, Toshiaki Sai), has awarded its 14th “Japan Research Foundation for Clinical Pharmacology Research Award” to five young researchers.
Award recipients are selected from research papers submitted from projects funded with subsidies from the foundation, and innovative research projects with expectations for future development are eligible for the award.
The Foundation hopes that this award will motivate young clinical pharmacology researchers who are involved in the establishment of appropriate drug treatments and encourage future research results. The awards ceremony and presentation of research themes will be held on November 16, 2021.
*The mission of the Foundation is to promote clinical pharmacology and foster the development of clinical pharmacologists. The Foundation was established in 1975 and has worked on a variety of projects relating to clinical pharmacology, including promotion of research and overseas studies for Japanese researchers.
Recipients of the 14th Japan Research Foundation for Clinical Pharmacology Research Award
Recipient
|
Organization
|
Research theme
|
Ogawa Youichi
|
Graduate School of Medicine, the Department of Dermatology, University of Yamanashi
|
Urinary lipocalin-2 could be a promising biomarker to predict the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis
|
Sakata-Yamagimoto Mamiko
|
Department of Hematology, Faculty of Medicine, University of Tsukuba
|
Therapeutic approach targeting aberrant activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma
|
Zamami Yoshito
|
Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School
|
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data to facilitate drug repositioning
|
Suzuki Yosuke
|
Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University
|
Physiologic factors associated with OATP1B activity in vivo
|
Fukudo Masahide
|
Department of Pharmacy, Sapporo Medical University Hospital
|
Evaluation of pharmacokinetics/pharmacodynamics and anti-drug antibody of PD-1 blockers
|